Changzheng Chen, PhD
Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Article
Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories
June 11, 2015
Reducing functional impairment in patients with major depressive disorder is critical for optimizing treatment outcomes and achieving long-term wellness. In this post hoc analysis, improvement in functional impairment in...
